aTYR PHARMA INC - COMMON STOCK (ATYR) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2019 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
ATYR on Nasdaq
Shares outstanding
97,996,626
Price per share
$0.78
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
60,876,849
Total reported value
$43,917,863
% of total 13F portfolios
0%
Share change
-5,415,477
Value change
-$49,484,419
Number of holders
98
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of aTYR PHARMA INC - COMMON STOCK (ATYR) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FEDERATED HERMES, INC. 11% -39% $55,463,739 -$21,682,577 10,544,437 -28% Federated Hermes, Inc. 30 Sep 2025
BlackRock, Inc. 6.5% $18,674,083 5,763,606 BlackRock, Inc. 30 Jun 2025
VANGUARD GROUP INC 5.2% $15,082,356 4,655,048 The Vanguard Group 30 Jun 2025
Point72 Asset Management, L.P. 3.2% $8,109,259 2,845,354 Point72 Asset Management, L.P. 31 Mar 2025

As of 30 Sep 2025, 98 institutional investors reported holding 60,876,849 shares of aTYR PHARMA INC - COMMON STOCK (ATYR). This represents 62% of the company’s total 97,996,626 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of aTYR PHARMA INC - COMMON STOCK (ATYR) together control 59% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FMR LLC 15% 14,697,995 +10% 0% $10,603,134
FEDERATED HERMES, INC. 11% 10,544,437 -28% 0.01% $7,606,757
BlackRock, Inc. 6.6% 6,473,884 +12% 0% $4,670,259
VANGUARD GROUP INC 5.7% 5,630,935 +21% 0% $4,059,904
UBS Group AG 4.6% 4,505,955 +158% 0% $3,248,793
STATE STREET CORP 4.3% 4,196,166 +238% 0% $3,027,114
GEODE CAPITAL MANAGEMENT, LLC 2.2% 2,178,203 +3.8% 0% $1,571,682
MILLENNIUM MANAGEMENT LLC 1.9% 1,890,921 +18% 0% $1,364,110
MORGAN STANLEY 0.72% 710,341 +173% 0% $512,440
GSA CAPITAL PARTNERS LLP 0.72% 706,731 +42% 0.04% $510,000
GOLDMAN SACHS GROUP INC 0.7% 688,165 +1797% 0% $496,443
NORTHERN TRUST CORP 0.69% 674,122 -1% 0% $486,312
TANG CAPITAL MANAGEMENT LLC 0.68% 671,134 0% 0.02% $484,156
Tikvah Management LLC 0.47% 460,833 -81% 0.1% $332,445
STATE OF WISCONSIN INVESTMENT BOARD 0.45% 438,262 0% $316,162
Ensign Peak Advisors, Inc 0.42% 414,732 +76% 0% $299,188
Artia Global Partners LP 0.38% 372,276 0.05% $268,560
BARCLAYS PLC 0.35% 341,359 +15% 0% $246,257
XTX Topco Ltd 0.32% 312,410 0.01% $225,373
WELLINGTON MANAGEMENT GROUP LLP 0.3% 289,231 +35% 0% $208,651
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.27% 261,043 +0.96% 0% $188,316
FLPUTNAM INVESTMENT MANAGEMENT CO 0.24% 235,255 +466% 0% $169,713
Brevan Howard Capital Management LP 0.24% 234,613 0% $168,922
Nuveen, LLC 0.23% 227,941 +17% 0% $164,436
JANE STREET GROUP, LLC 0.23% 227,785 +525% 0% $164,324

Institutional Holders of aTYR PHARMA INC - COMMON STOCK (ATYR) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 45,332 $34,921 -$11,632 $0.78 4
2025 Q3 60,876,849 $43,917,863 -$49,484,419 $0.72 98
2025 Q2 66,359,568 $336,444,770 +$26,875,817 $5.07 109
2025 Q1 61,756,683 $186,507,450 +$18,904,934 $3.02 86
2024 Q4 54,865,656 $198,612,160 +$28,551,641 $3.62 77
2024 Q3 47,854,177 $84,222,647 -$407,421 $1.76 54
2024 Q2 48,123,448 $75,072,910 +$8,931,063 $1.56 45
2024 Q1 41,805,838 $81,517,658 +$1,475,515 $1.95 56
2023 Q4 41,213,560 $58,107,233 +$3,551,996 $1.41 45
2023 Q3 37,131,978 $58,669,207 +$2,049,115 $1.58 41
2023 Q2 35,668,257 $77,043,513 +$2,315,557 $2.16 41
2023 Q1 34,663,995 $72,793,910 +$35,336,607 $2.10 37
2022 Q4 18,353,120 $40,192,707 -$2,084,850 $2.19 35
2022 Q3 19,009,787 $57,028,570 +$782,323 $3.00 31
2022 Q2 18,767,627 $53,115,149 -$3,103,801 $2.83 35
2022 Q1 19,627,491 $105,008,778 -$6,161,774 $5.35 38
2021 Q4 20,534,388 $153,393,033 +$3,923,414 $7.47 45
2021 Q3 18,824,963 $170,928,000 +$109,402,310 $9.08 39
2021 Q2 6,787,411 $33,118,000 +$4,920,158 $4.88 23
2021 Q1 5,779,531 $25,721,000 +$195,254 $4.45 19
2020 Q4 5,760,740 $22,351,000 -$373,364 $3.88 18
2020 Q3 5,633,800 $18,195,000 +$464,498 $3.23 19
2020 Q2 5,472,169 $24,295,000 +$1,598,380 $4.44 21
2020 Q1 5,114,483 $14,319,000 +$9,326,718 $2.80 21
2019 Q4 1,793,570 $7,478,000 +$296,912 $4.17 13
2019 Q3 1,718,322 $6,014,000 +$4,151,946 $3.50 13
2019 Q2 530,377 $193,000 +$193,000 $0.36 5